Conduit Pharmaceuticals (CDT) Institutional Ownership $2.55 -0.21 (-7.61%) Closing price 04:00 PM EasternExtended Trading$2.48 -0.06 (-2.55%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Conduit Pharmaceuticals (NASDAQ:CDT)CurrentInstitutional OwnershipPercentage3.29%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$6.92MNumber ofInstitutional Sellers(last 12 months)0 Get CDT Insider Trade Alerts Want to know when executives and insiders are buying or selling Conduit Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Conduit Pharmaceuticals Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails1/30/2025Rhumbline Advisers1,028,702$71K0.0%+5,034.0%1.000% (Data available from 1/1/2016 forward) CDT Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of CDT shares? During the previous two years, the following institutional investors and hedge funds held shares of Conduit Pharmaceuticals shares: Rhumbline Advisers ($71K).Learn more on CDT's institutional investors. What percentage of Conduit Pharmaceuticals stock is owned by institutional investors? 3.29% of Conduit Pharmaceuticals stock is owned by institutional investors. Learn more on CDT's institutional investor holdings. Which institutional investors have been buying Conduit Pharmaceuticals stock? The following institutional investors have purchased Conduit Pharmaceuticals stock in the last 24 months: Rhumbline Advisers ($1.01M). How much institutional buying is happening at Conduit Pharmaceuticals? Institutional investors have bought a total of 1,008,665 shares in the last 24 months. This purchase volume represents approximately $6.92M in transactions. Related Companies Praxis Precision Medicines Major Shareholders Xencor Major Shareholders Ardelyx Major Shareholders Day One Biopharmaceuticals Major Shareholders ANI Pharmaceuticals Major Shareholders Arvinas Major Shareholders Arcus Biosciences Major Shareholders Ocular Therapeutix Major Shareholders Syndax Pharmaceuticals Major Shareholders Calliditas Therapeutics AB (publ) Major Shareholders This page (NASDAQ:CDT) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredTrump’s back in the oval office. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. And he says 2025 could be...Weiss Ratings | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Conduit Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Conduit Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
